Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2341 to 2355 of 7685 results

  1. ENDURALIFE powered CRT-D devices for treating heart failure (MTG33)

    Evidence-based recommendations on ENDURALIFE-powered CRT-D devices for treating heart failure.

    Medical technologies guidance
    Last updated
    21 July 2021
    View recommendations

    Sections for MTG33

  2. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer TSID 12040

    Awaiting development [GID-TA11591] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors TSID 12064

    Awaiting development [GID-TA11594] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Aflibercept for untreated retinopathy in babies born preterm TS ID 11943

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development [GID-NG10216] Expected publication date: TBC

    NICE guideline
    In development

  6. Eszopiclone for treating insomnia TS ID 12020

      Status ...

    Technology appraisal guidance
    Topic selection

  7. Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG TSID 12042

    Awaiting development [GID-TA11592] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over TSID 12036

    Awaiting development [GID-TA11596] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]

    Awaiting development [GID-TA11278] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development [GID-IPG10409] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  11. Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044]

    In development [GID-TA10930] Expected publication date: 28 May 2025

    Technology appraisal guidance
    In development

  12. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    In development [GID-TA11228] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

    In development [GID-TA11397] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  14. Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

    Awaiting development [GID-TA11468] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]

    In development [GID-TA10620] Expected publication date: TBC

    Technology appraisal guidance
    In development